A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects.
Cancer Chemother Pharmacol
; 88(5): 879-886, 2021 11.
Article
en En
| MEDLINE
| ID: mdl-34355250
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Biosimilares Farmacéuticos
/
Trastuzumab
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
Cancer Chemother Pharmacol
Año:
2021
Tipo del documento:
Article